Evidence map›Paper›PMID 31339935›Full record

ArticlePloS one2019

Empiric treatment of pulmonary TB in the Xpert era: Correspondence of sputum culture, Xpert MTB/RIF, and clinical diagnoses.

Emily A Kendall, Caleb Kamoga, Peter J Kitonsa, Annet Nalutaaya, Phillip P Salvatore, Katherine Robsky, Olga Nakasolya, James Mukiibi, David Isooba, Adithya Cattamanchi and 3 more

Open access · goldAbstract readComparative StudyEvaluation Study
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Silicotuberculosis: a critical narrative review.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  7. Article
  8. Article
  9. Evidence for Tuberculosis in Individuals With Xpert Ultra "Trace" Sputum During Screening of High-Burden Communities.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. The Spectrum of Tuberculosis Disease in an Urban Ugandan Community and Its Health Facilities.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Emily A KendallDivision of Infectious Diseases and Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, MD, United States America.ORCID 0000-0002-0083-422X
Caleb KamogaUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Peter J KitonsaUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Annet NalutaayaUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Phillip P SalvatoreDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States America.
Katherine RobskyUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Olga NakasolyaUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
James MukiibiUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
David IsoobaUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Adithya CattamanchiUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Midori Kato-MaedaDivision of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, United States America.
Achilles KatambaUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
David W DowdyUganda Tuberculosis Implementation Research Consortium, Makerere University, Kampala, Uganda.
Makerere University · UGJohns Hopkins University · USUniversity of California, San Francisco · US

Funding

Hotspot versus clinic-based active case finding for TB in Uganda: A pragmatic randomized trialR01HL138728 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI David Wesley Dowdy, Emily A Kendall · 2017 to 2026
$5.4M
Translational modeling of individual- and population-level outcomes of novel tuberculosis drug regimensK08AI127908 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KENDALL, EMILY A · 2017 to 2021
$879k
NHLBI NIH HHS R01 HL138728NIAID NIH HHS K08 AI127908
6 · The paper itself

Abstract

backgroundClinical tuberculosis diagnosis and empiric treatment have traditionally been common among patients with negative bacteriologic test results. Increasing availability of rapid molecular diagnostic tests, including Xpert MTB/RIF and the new Xpert Ultra cartridge, may alter the role of empiric treatment.

methodsWe prospectively enrolled outpatients age > = 15 who were evaluated for pulmonary tuberculosis at three health facilities in Kampala, Uganda. Using sputum mycobacterial culture, interviews, and clinical record abstraction, we estimated the accuracy of clinical diagnosis relative to Xpert and sputum culture and assessed the contribution of clinical diagnosis to case detection.

resultsOver a period of 9 months, 99 patients were diagnosed with pulmonary tuberculosis and subsequently completed sputum culture; they were matched to 196 patients receiving negative tuberculosis evaluations in the same facilities. Xpert was included in the evaluation of 291 (99%) patients. Compared to culture, Xpert had a sensitivity of 92% (95% confidence interval 83-97%) and specificity of 95% (92-98%). Twenty patients with negative Xpert were clinically diagnosed with tuberculosis and subsequently had their culture status determined; two (10%) were culture-positive. Considering all treated patients regardless of Xpert and culture data completeness, and considering treatment initiations before a positive Xpert (N = 4) to be empiric, 26/101 (26%) tuberculosis treatment courses were started empirically. Compared to sputum smear- or Xpert-positive patients with positive cultures, empirically-treated, Xpert-negative patients with negative cultures had higher prevalence of HIV (67% versus 37%), shorter duration of cough (median 4 versus 8 weeks), and lower inflammatory markers (median CRP 7 versus 101 mg/L).

conclusionJudged against sputum culture in a routine care setting of high HIV prevalence, the accuracy of Xpert was high. Clinical judgment identified a small number of additional culture-positive cases, but with poor specificity. Although clinicians should continue to prescribe tuberculosis treatment for Xpert-negative patients whose clinical presentations strongly suggest pulmonary tuberculosis, they should also carefully consider alternative diagnoses.

Indexed as

Diagnostic Tests, RoutineAdultAntibiotics, AntitubercularCase-Control StudiesDrug Resistance, BacterialFemaleHumansMaleMicrobiological TechniquesMolecular Diagnostic TechniquesMycobacterium tuberculosisPolymerase Chain ReactionReproducibility of ResultsSensitivity and SpecificitySputumTime-to-TreatmentAntibiotics, Antitubercular

Identifiers

PMID31339935
PMCPMC6655770
OpenAlexW2963438478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.